Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cetuximab combined with FOLFOX4 as the first-line treatment for advanced gastric cancer: report of 25 cases from a single institution.

Hepato-gastroenterology - 1 Jun 2012

Shi Min, Ji Jun, Wu Jun, Ma Tao, Liu Ying, Zhou Chen-Fei, Su Yang, Ye Zheng-Bao, Zhang Jun, Zhu Zheng-Gang

Abstract excerpt

BACKGROUND/AIMS: To assess efficacy and safety of cetuximab with FOLFOX4 as first-line treatment for advanced gastric cancer. METHODOLOGY: Cetuximab was administered at 400mg/m2 followed by 250mg/m2 weekly, or 500mg/m2 every 2 weeks. FOLFOX4 regimen was given every 2 weeks (oxaliplatin 85mg/m2, LFA 200mg/m2, 5-FU 400mg/m2 bolus and 600mg/m2 22-hour continuous infusion), for a maximum of 12 cycles, or until the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Fluorouracil

Share to Leucovorin

Share to Organoplatinum Compounds

Share to ras Proteins

Share to Stomach Neoplasms

Source

Identifiers

PMID: 22281975
DOI: 10.5754/hge11874

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cetuximab combined with FOLFOX4 as the first-line treatment for advanced gastric cancer: report of 25 cases from a single institution.PMID 22281975Read ↗

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Semantic proximity Read ↗

[Clinicopathological and molecular features of two cases of early gastric adenocarcinoma with enteroblastoid differentiation treated by endoscopic submucosal dissection].Semantic proximity Read ↗

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancerSemantic proximity Read ↗

Advanced gastric cancer: Current treatment landscape and future perspectives.Semantic proximity Read ↗

Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.Semantic proximity Read ↗

Evaluation of Quality of Life in Patients With Gastric Adenocarcinoma Receiving Chemoradiotherapy: a Cross-sectional StudySemantic proximity Read ↗

A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.Semantic proximity Read ↗

Pathological complete response to nivolumab, S1, oxaliplatin, and radiation in a patient with gastric cancer: A case reportSemantic proximity Read ↗

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.Semantic proximity Read ↗

Gastric cancer patient with c-MET amplification treated with crizotinib after failed multi-line treatment: A case report and literature reviewSemantic proximity Read ↗

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

A Case of Multiple Gastric Adenocarcinoma of Fundic Gland typeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.